04 May
2026
16:30 E.S.T.

Cellectis to Report First Quarter Financial Results on May 11, 2026

Read more

27 Apr
2026
10:14 E.S.T.

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

Read more

13 Apr
2026
04:30 E.S.T.

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform

Read more

19 Mar
2026
19:00 E.S.T.

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

Read more

12 Mar
2026
16:30 E.S.T.

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Read more

08 Jan
2026
16:30 E.S.T.

Cellectis Announces 2026 Strategy and Catalysts

Read more

15 Dec
2025
16:50 E.S.T.

Cellectis Announces Arbitral Decision in Dispute with Servier

Read more

08 Dec
2025
01:30 E.S.T.

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

Read more

19 Nov
2025
06:20 E.S.T.

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

Read more

07 Nov
2025
16:30 E.S.T.

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more